Effect of PCSK9 Inhibitors on Chronic Total Occlusions
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin
type-9 (PCSK9) inhibitors added to regular statin therapy on neointimal hyperplasia and
target lesion failure (TLF) in patients with chronic total occlusions (CTOs) undergoing
successful percutaneous coronary intervention (PCI).